Published online Jun 27, 2021. doi: 10.4254/wjh.v13.i6.686
Peer-review started: February 18, 2021
First decision: March 16, 2021
Revised: March 27, 2021
Accepted: May 20, 2021
Article in press: May 20, 2021
Published online: June 27, 2021
The Budd Chiari syndrome (BCS) is a rare disorder that results from partial or complete obstruction of the hepatic venous outflow in the absence of right heart failure.
There is a paucity of data on the in-hospital mortality of BCS as well its economic impact on the United States health care system.
This study aimed to evaluate trends in mortality, length of hospital stays and resource utilization among inpatients with BCS.
Retrospective study where data were extracted from the National Inpatient Sample (NIS) from 1998 to 2017. To make inferences regarding the national estimates for the total number of BCS discharges across the study period, sample weights were applied to each admission per recommendations from the NIS.
During the study period, there were 3591 (8.73%) in-patient deaths. The overall in-hospital mortality rate among BCS patients decreased from 18% in 1998 to 8% in 2017; the mortality decreased by 4.41% every year. The average of length of stay was 8.8 d and it consistently decreased by 2.04% from 12.7 d in 1998 to 7.6 d in 2017.The average total charges during the time period was $94440 and the annual percentage change increased by 1.15%
The in-hospital mortality rate for patients admitted with BCS in the United States has reduced between 1998 and 2017 while total charges continued to increase.
Using a large national database, we analyzed the mortality and socioeconomic impact of BCS hospitalizations in the United States with a high degree of granularity.